BSPCE, free shares, stock options and management packages in France 2026

Quick answer. In 2026, four equity tools structure stock-based compensation in France: BSPCE (article 163 bis G of the French Tax Code, reserved for companies less than 15 years old majority-owned by individuals), free shares or AGA (articles L. 225-197-1 and following of the French Commercial Code, capped at 10% of share capital, with a 20% specific employer contribution since the 2018 social security finance act), stock options (articles L. 225-177 and following, exercise price set at grant date with a maximum 20% discount versus average market price) and management packages negotiated in M&A or LBO contexts. The useful distinction for executives is threefold: the exercise gain (difference between real value and exercise or acquisition price) follows a specific regime per instrument, the subsequent capital gain on sale falls under the 30% flat tax (article 200 A of the French Tax Code) or progressive income tax on election, and documentation of the grant-date value drives tax security.

A French equity plan is not a perk handed out at the end of a board meeting. It changes the cap table, payroll, the beneficiary's personal tax exposure, investor rights and the ability to recruit key talent. Since the BOFiP commentary BOI-RSA-ES-20-40-40 published in 2025, the French tax authority distinguishes more clearly between the exercise gain (determined at exercise date and taxed according to the beneficiary's seniority), the subsequent capital gain on sale (flat tax or progressive scale) and the grant-date valuation (which must rely on a defensible method: DCF, comparables or recent funding round price). At Hayot Expertise, registered with the Paris Ile-de-France Order of Chartered Accountants, we have supported more than 80 BSPCE, AGA and stock-option grants since 2020 for funded startups (pre-seed to Series B) and SMEs under LBO. This article reflects the rules in force on 19 May 2026 and crystallises the practical trade-offs we present in committee with executive teams.

The right tool depends on three variables: the issuing company, the beneficiaries' profile and the liquidity calendar. BSPCE remain the natural instrument for eligible young startups: French company subject to corporate income tax, unlisted (or listed on Euronext Growth with market cap below EUR 150m), less than 15 years old, capital held directly or indirectly above 25% by individuals or themselves-eligible companies, headquartered in France or in an EEA state. AGA suit more mature groups or broad-based teams, subject to shareholder authorisation for up to 38 months, a global cap of 10% of share capital (15% in EU-defined SMEs), an acquisition period of at least one year and a combined acquisition plus holding period of at least two years (article L. 225-197-1, II of the French Commercial Code). Stock options require a financial effort from the beneficiary at exercise (paying the exercise price), making them a natural tool for senior executives with sufficient purchasing power or for mature listed structures. The management package must be treated as a documented investment operation, especially in M&A or LBO contexts: without genuine economic risk and market-based valuation, the requalification risk into salary (with retroactive URSSAF contributions) is central.

Employer cost and net beneficiary gain in 2026 — summary. BSPCE: zero employer social charge, exercise gain taxed at the 31.4% flat tax (12.8% income tax + 18.6% social levies) if the beneficiary has been in office at least three years in the issuing company; otherwise progressive income tax scale + 18.6% social levies (article 163 bis G I of the French Tax Code). AGA: 20% specific employer contribution at acquisition date (due even without a sale), acquisition gain taxed at progressive income tax with a 50% allowance up to EUR 300,000 of gain (2018 social security finance act), CSG/CRDS 9.7%. Stock options: 31.4% employer contribution on the option value at grant (article L. 137-13 of the Social Security Code), exercise gain taxed at progressive income tax + CSG/CRDS 9.7%. Management package: variable regime depending on qualification (capital instruments, warrants, hurdle preferred shares), with requalification risk into employment income if the investment is not real.

• BSPCE eligibility under art. 163 bis G CGI: company subject to French CIT, unlisted or listed on Euronext Growth (cap < EUR 150m), incorporated less than 15 years ago, capital held at least 25% by individuals or themselves-eligible companies, registered in France or in an EEA state.
• Pre and post-grant cap table, including fully diluted option pool. Model the impact of a future round pre-money vs post-money (see cap table dilution simulator).
• Formalised corporate decisions: for BSPCE, AGE voting at two-thirds majority (article L. 228-91 of the French Commercial Code); for AGA, AGE delegating to the board or president for up to 38 months; for stock options, AGE delegating to the board for up to 38 months.
• Grant-date valuation documented: for BSPCE, the exercise price must be at least equal to the last funding round value, unless an independent valuation report (DCF, comparables) justifies a lower price. An undocumented discount triggers reassessment risk on the value of the benefit.
• Payroll and personal tax treatment without promising a guaranteed net gain: for AGA, the 20% employer contribution is due at acquisition even without a sale; for stock options, the 30% employer contribution is due at grant.
• Consistency with the shareholders agreement: vesting clauses (typically 4 years with 1-year cliff), good leaver / bad leaver, drag along, tag along, secondary liquidity, treatment of departing beneficiaries.
• Social and tax filings: monthly DSN for the beneficiary, URSSAF employer contribution (CSS art. L. 137-13 for stock options, L. 137-14 for AGA), specific filing at exercise (BSPCE) or acquisition (AGA).
• Annual tracking: beneficiary register, vesting status, exercises and sales, cap table update, beneficiary income tax return (boxes 1TT/1UT).

Anonymised client case — Paris B2B SaaS startup, Series A in progress. A French SAS incorporated in 2022 (capital held 68% by three individual founders), 18-month runway, EUR 1.8m ARR, prepares a Series A round of EUR 6m at a pre-money valuation of EUR 24m (post-money EUR 30m). Before closing, the board wants to grant an equity plan to 12 key contributors (CTO, lead engineer, head of sales, 9 senior individual contributors). The HR director initially proposes AGA 'to avoid tax complexity'. Our analysis at steering committee: for a BSPCE-eligible company, the employer-cost gap is significant.

Quantitative comparison on a 3% post-money pool (value EUR 900,000). AGA option: the company pays a 20% employer contribution on the share value at acquisition, i.e. about EUR 180,000 of cash out at 2 years, regardless of beneficiary liquidity. For the beneficiary (41% marginal income tax), the acquisition gain is taxed at progressive income tax with 50% allowance (up to EUR 300,000) plus CSG/CRDS 9.7%. BSPCE option: zero employer social charge, and a beneficiary in office for at least three years benefits from the 31.4% flat tax on the exercise gain (12.8% IT + 18.6% social levies), an effective gap of roughly 18 points versus the AGA progressive scale.

Hayot Expertise recommendation. Priority BSPCE plan for the 9 contributors in office for more than three years, with the exercise price set at the Series A post-money value (EUR 5.40/share) to secure the absence of BOFiP discount. Secondary AGA plan for the 3 new joiners (CTO, head of sales and one lead engineer recruited in 2026), since they are not eligible for the 31.4% BSPCE flat tax (activity duration < 3 years at probable exit), with the 20% employer contribution budgeted at grant. Standard vesting: 4 years, 1-year cliff, double-trigger acceleration on change of control. Documentation: 28-page BSPCE plan rules, AGE minutes, statutory auditor or appointed auditor report for the AGA (article L. 225-197-1 of the French Commercial Code), update of the beneficiary register and post-grant cap table. Total support cost: EUR 4,800 excl. VAT, saving EUR 180,000 of employer contribution versus the originally envisaged all-AGA scenario.

Our chartered accountant's view. Across the fifty-plus equity plans we have supported since 2022, three mistakes recur and trigger contentious renegotiation after the next funding round.

Mistake n. 1 — confusing tax and HR strategy. Many executives pick the instrument solely on the flat-tax vs progressive-scale gap. Yet HR trade-offs (vesting duration, leaver treatment, internal signal, sector tech practice) often outweigh the tax delta. A well-built AGA plan can outperform a poorly calibrated BSPCE plan if the beneficiary leaves before exercise. We always rebuild the HR strategy first (who to retain, for how long, with what financial signal), then the available equity envelope, and only then the tax instrument.

Mistake n. 2 — under-documenting the exercise or subscription price. The 2025 BOFiP commentary BOI-RSA-ES-20-40-40 clarified that the grant-date value must rely on a defensible method: last funding round price, DCF report, sector comparables or independent third-party valuation. An undocumented discount turns the gap into a taxable benefit at progressive income tax plus URSSAF contributions, with potential reassessments over three years. On a recent file (post-Series B startup, 2024 grant deemed 'too low'), the reassessment covered EUR 340,000 of social and income tax, plus penalties.

Mistake n. 3 — ignoring the shareholders agreement and leaver clauses. A BSPCE plan granted without coordination with the shareholders agreement generates two risks: a bad-leaver beneficiary may keep already-vested BSPCE if the call option is not formalised; a liquidity event (sale, IPO) without a drag along clause forces individual buy-out of each beneficiary, which can block the transaction. We systematically mirror clauses (accelerated vesting, leaver, drag, tag, secondary liquidity) in both the plan rules AND the shareholders agreement. Our corporate legal coordination service aligns this dual documentation with the executive's corporate lawyer.

The cabinet is registered with the Paris Ile-de-France Order of Chartered Accountants. We work in pluridisciplinary teams (M&A counsel, tax adviser, valuation specialist) on sensitive equity plans, in particular for Series A rounds or LBO buy-outs.

The underestimated risk is insufficiently documented exercise value. An exercise price arbitrarily set at par value (EUR 1 per share, say) while the last round values the share at EUR 12 automatically triggers a benefit-in-kind qualification for the difference (EUR 11/share), unless an independent valuation report justifies the discount (illiquidity, minority, unvested rights). The French tax authority may then recharacterise the operation as additional salary, with progressive income tax reassessment, CSG/CRDS 9.7% and URSSAF employee and employer contributions. On a 50,000 BSPCE plan granted to a CTO, the exposure can exceed EUR 200,000 in reassessment.

Second risk — AGA granted shortly before a liquidity event. When an AGA is granted 6 to 12 months before a sale, the tax authority may consider the grant-date value was knowingly understated to turn a vendor consideration into a low-taxed capital gain. The BOI-RSA-ES-20-20-10 sets out the defence conditions: independence of the decision, prior plan, absence of a sale promise at grant.

Third risk — management package without real economic risk. In LBO contexts, ABSA, ratchet warrants or hurdle preferred shares can be requalified as additional compensation if the executive does not invest a meaningful amount (typically 2-5% of annual compensation), if the gain is virtually guaranteed by the mechanism (1:10 ratchet with no real downside) or if the legal documentation does not identify a genuine market uncertainty. The French Conseil d'Etat (CE, 13 July 2021, 'Wendel') confirmed the requalification possibility when the instrument primarily rewards an employment function.

Fourth risk — the 20% AGA employer contribution missing from the budget. Many executives budget an AGA without integrating the 20% specific employer contribution (article L. 137-13 of the Social Security Code), due at the acquisition date even without a sale or beneficiary gain. On a 5% capital plan in a company valued at EUR 30m, that is EUR 300,000 of cash out at 2 years, independent of any liquidity. Without anticipated budget, the grant triggers a cash tension at the exact moment the startup invests in growth.

• Define priority beneficiaries and maximum acceptable fully diluted dilution: typically 8-15% BSPCE pool at Series A, 1-3% collective AGA pool for broad retention, 1-5% executive package in LBO contexts.
• Choose the main mechanism: BSPCE if eligible under art. 163 bis G CGI, AGA if not eligible or for broad collective plans, stock options if financial effort is feasible, management package in LBO only with real co-investment and independent valuation.
• Validate the valuation method before corporate approval: for BSPCE, last round value or DCF report; for AGA and stock options, market or average price (listed); for management packages, mandatory independent report in sophisticated structures.
• Align the plan with the shareholders agreement and next funding round: mirrored leaver clauses, drag along, tag along, secondary liquidity, pre- and post-acquisition leaver treatment.
• Budget employer contributions: 20% AGA (CSS art. L. 137-14), 30% stock options (CSS art. L. 137-13), zero for BSPCE. Over a 3-year plan, the cash-out gap can exceed EUR 200,000 for an SME.
• Plan annual tracking: up-to-date beneficiary register, vesting status, exercises and sales, DSN and URSSAF filings, fully diluted cap table update, quarterly board reporting.

• BSPCE — art. 163 bis G CGI and BOFiP BOI-RSA-ES-20-40-40 2025: for shares subscribed from 1 January 2025, reinforced distinction between exercise gain (taxed per seniority) and capital gain on sale (30% flat tax). Documentation of exercise value mandatory.
• AGA — art. L. 225-197-1 of the French Commercial Code: 10% capital cap (15% in SMEs), acquisition period ≥ 1 year, combined holding period ≥ 2 years, 38-month AGE max, 20% employer contribution at acquisition.
• Stock options — art. L. 225-177 of the French Commercial Code: maximum 20% discount versus the 20-session average price (listed companies), exercise price fixed at grant, 30% employer contribution at grant.
• Management package — requalification risk (CE Wendel 13 July 2021): real co-investment (2-5% of compensation), independent valuation, genuine market uncertainty, pluridisciplinary legal documentation.
• Social and tax regime for non-French resident beneficiaries: withholding tax at exercise (art. 182 A bis CGI), bilateral tax treaties to verify (notably US, UK, Israel, Germany), double-taxation risk without local cabinet coordination.
• Coordination with the executive's holding: contribution of shares or BSPCE under tax deferral (art. 150-0 B ter CGI) to postpone the capital gain taxation, subject to strict reinvestment conditions.

• BSPCE: practical 2026 guide for French startups
• French AGA free shares 2026 taxation
• management package tax pitfalls before an investor
• shareholders agreement: 15 vital clauses for 2026
• 12 term sheet clauses to negotiate
• ratchet, liquidation preference and anti-dilution
• startup valuation methods to defend a price
• share contribution to a holding (art. 150-0 B ter CGI)
• French payroll and employee benefits
• corporate legal coordination
• executive's holding tax support
• accounting for French tech startups
• dilution and cap table simulator
• startup valuation simulator DCF and comparables
• executive remuneration simulator

• Légifrance - CGI art. 163 bis G (régime fiscal des BSPCE)
• BOFiP - BSPCE, régime fiscal applicable aux titres souscrits à compter du 1er janvier 2025 (BOI-RSA-ES-20-40-40)
• BOFiP - BSPCE, champ d’application (BOI-RSA-ES-20-40-10)
• Légifrance - Code de commerce, article L.225-197-1 sur les actions gratuites (AGA)
• Légifrance - Code de commerce, article L.225-177 sur les stock-options
• BOFiP - Stock-options : régime fiscal du gain de levée (BOI-RSA-ES-20-10-20)
• BOFiP - Actions gratuites : régime fiscal et social (BOI-RSA-ES-20-20-10)
• URSSAF - Contribution patronale spécifique sur AGA et stock-options

Freshness note: Current as of 3 May 2026.